The relationship of vitamin d serum pre-chemotherapy with myeloid toxicity in locally advanced breast cancer received cyclophosphamide, doxorubicin, and 5-fluorouracil neoadjuvant

Background: Myeloid toxicity is one of the effects caused by patients undergoing chemotherapy and potentially life-threatening. This study aimed to determine the relationship between serum vitamin D levels in pre-cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) chemotherapy, and the occurrence of myeloid toxicity in patients with locally advanced breast cancer (LABC) undergoing neoadjuvant chemotherapy. Methods: A cohort study design was enrolled in patients with LABC undergoing CAF neoadjuvant chemotherapy. The independent variable was the level of vitamin D in the blood, and the dependent variable was chemotherapy myeloid toxicity. Results: In this study, 70% of patients had low vitamin D levels. There were significant differences in hemoglobin (p = 0.000), leukocytes (p = 0.028), platelets (p = 0.018), neutrophil (p = 0.003) after chemotherapy. Moreover, there were relationship between changes in hemoglobin levels (p = 0.006), leukocytes (p = 0.024), platelets (p = 0.03), and neutrophils (p = 0.02) after chemotherapy with low levels of vitamin D before chemotherapy. Low levels of pre-chemotherapy vitamin D of LABC patients was statistically correlated with myeloid toxicity after CAF neoadjuvant chemotherapy (p = 0.014). Conclusion: Pre-chemotherapy serum vitamin D levels are associated with the occurrence of myeloid toxicity in LABC patients undergoing CAF neoadjuvant chemotherapy.